Chia Tai Enterprises International Limited (3839.HK)
HKD 1.64
(0.0%)
HKD 1.64
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - USD | -175.68% |
| 2022 | -1.64 Million USD | -112.36% |
| 2021 | 13.3 Million USD | -30.17% |
| 2020 | 19.05 Million USD | -4.19% |
| 2019 | 19.88 Million USD | -20.2% |
| 2018 | 24.92 Million USD | 27.82% |
| 2017 | 19.49 Million USD | 37.12% |
| 2016 | 14.21 Million USD | -10.74% |
| 2015 | 15.92 Million USD | -44.98% |
| 2014 | 28.95 Million USD | 62.26% |
| 2013 | 17.84 Million USD | -15.4% |
| 2012 | 21.09 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -184 Thousand USD | 92.48% |
| 2024 Q2 | 408 Thousand USD | 321.74% |
| 2023 Q2 | -1.65 Million USD | -267.85% |
| 2023 Q4 | -2.44 Million USD | -348.32% |
| 2023 FY | -4.53 Million USD | -175.68% |
| 2023 Q3 | 985 Thousand USD | 159.7% |
| 2023 Q1 | 983 Thousand USD | -20.73% |
| 2022 FY | -1.64 Million USD | -112.36% |
| 2022 Q3 | -537 Thousand USD | -143.45% |
| 2022 Q4 | 1.24 Million USD | 330.91% |
| 2022 Q1 | 509 Thousand USD | -75.04% |
| 2022 Q2 | 1.23 Million USD | 142.83% |
| 2021 Q1 | 1 Million USD | 289.53% |
| 2021 FY | 13.3 Million USD | -30.17% |
| 2021 Q4 | 2.03 Million USD | 102.28% |
| 2021 Q3 | 1 Million USD | 10.04% |
| 2021 Q2 | 916 Thousand USD | -8.86% |
| 2020 Q2 | 314 Thousand USD | -45.01% |
| 2020 Q4 | 258 Thousand USD | 70.86% |
| 2020 Q3 | 151 Thousand USD | -51.91% |
| 2020 FY | 19.05 Million USD | -4.19% |
| 2020 Q1 | 571 Thousand USD | 83.6% |
| 2019 Q2 | 1.47 Million USD | -11.16% |
| 2019 Q1 | 1.65 Million USD | -25.21% |
| 2019 FY | 19.88 Million USD | -20.2% |
| 2019 Q4 | 311 Thousand USD | 26.94% |
| 2019 Q3 | 245 Thousand USD | -83.37% |
| 2018 Q4 | 2.21 Million USD | 3056.0% |
| 2018 Q2 | -673 Thousand USD | -144.39% |
| 2018 Q1 | 1.51 Million USD | 91.41% |
| 2018 FY | 24.92 Million USD | 27.82% |
| 2018 Q3 | -75 Thousand USD | 88.86% |
| 2017 Q4 | 792 Thousand USD | 1340.0% |
| 2017 Q2 | -864 Thousand USD | -237.14% |
| 2017 Q1 | 630 Thousand USD | -72.9% |
| 2017 FY | 19.49 Million USD | 37.12% |
| 2017 Q3 | 55 Thousand USD | 106.37% |
| 2016 Q3 | 871 Thousand USD | -63.48% |
| 2016 Q2 | 2.38 Million USD | 78.25% |
| 2016 Q1 | 1.33 Million USD | -52.87% |
| 2016 Q4 | 2.32 Million USD | 166.93% |
| 2016 FY | 14.21 Million USD | -10.74% |
| 2015 FY | 15.92 Million USD | -44.98% |
| 2015 Q4 | 2.83 Million USD | -25.99% |
| 2015 Q3 | 3.83 Million USD | 56.38% |
| 2015 Q2 | 2.45 Million USD | -22.42% |
| 2015 Q1 | 3.16 Million USD | -62.24% |
| 2014 Q4 | 8.37 Million USD | 115.94% |
| 2014 Q3 | 3.87 Million USD | 112.26% |
| 2014 Q2 | 1.82 Million USD | 0.0% |
| 2014 Q1 | 1.82 Million USD | 0.0% |
| 2014 FY | 28.95 Million USD | 62.26% |
| 2013 FY | 17.84 Million USD | -15.4% |
| 2012 FY | 21.09 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 100.0% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 100.0% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 100.0% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 100.0% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 100.0% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 100.0% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 100.0% |
| Tongfang Kontafarma Holdings Limited | - HKD | NaN% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 100.0% |
| SSY Group Limited | 1.63 Billion HKD | 100.0% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 100.0% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 100.0% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.0% |